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Molecular imaging plays an important role in the non-invasive diagnosis and the guiding or monitoring of disease
treatment. Different imaging modalities have been developed, and each method possesses unique strengths. While
a variety of molecules have been used previously in nuclear imaging, the exceptional properties of nanostructures
in recent research enable the deployment of accurate and efficient diagnostic agents using radionuclide-nanostructures.
This review focuses on the radionuclide labeling strategies of various nanostructures and their applications for
multimodality tumor imaging.
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Over the past decade, molecular imaging has emerged
and expanded rapidly due to its great potential for un-
derstanding biological reactions, detecting diseases in
early stages, providing accurate diagnosis, and visualizing
pathologic processes and cellular functions at the mo-
lecular and cellular level without perturbing the living
organism [1-5]. Several types of tools have been developed
for molecular imaging, such as magnetic resonance imaging
(MRI), computed tomography (CT), positron emission tom-
ography (PET), single photon emission computed tomog-
raphy (SPECT), contrast enhanced ultrasound (CEUS),
and optical fluorescence [6]. PET, SPECT, and other
radionuclide-based imaging methods have been exten-
sively used in biomedical and clinical fields due to
their excellent features of high sensitivity, easy quanti-
tation, and strong penetration through tissue [7-10].
In the case of nuclear molecular imaging tools (PET and
SPECT), radionuclide-labeled substances are used as con-
trast agents. Generally, radionuclides are linked via a che-
lating agent to targeting components, such as antibodies,
antibody fragments, peptides, proteins, oligonucleotides,
or receptor ligands [11-16]. Recently, nanoparticles have
been noted as a remarkable radionuclide carrier due to* Correspondence: jmnam@snu.ac.kr
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in any medium, provided the original work is ptheir chemical and biological stability, high loading
capacity, noteworthy physicochemical properties, and
practically limitless surface-functionalization [17]. Although
several functionalization methods using chelating agents
have been suggested and developed [18-24], those methods
have numerous limitations for nuclear molecular imaging
because the radionuclides originally incorporated with che-
lating agents can detach from those molecules in vivo
[25-27]. These instabilities may induce false target detec-
tion, which decreases the accuracy of diagnostic informa-
tion. Therefore, functionalization methods free of chelating
agents have been sought recently as a way to overcome
those drawbacks [28-32].
For practical purposes, molecular imaging tools are
not sufficient by themselves due to their inherent limita-
tions. For example, while the imaging modes PET and
SPECT are highly sensitive, quantitative, and show good
tissue penetration depth, they are limited by their low
spatial resolution [6]. Therefore, the combination of two
or more molecular imaging tools, otherwise known as
multimodality imaging, should be used to overcome the
deficiencies of individual imaging modes to ensure the
accuracy of molecular imaging applications. Moreover,
the unique properties of nanostructures can be used to
their advantage to lessen the amount of radionuclide used
and maximize the benefits of multimodality imaging.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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beling strategies on various nanostructures and their ap-
plications of multimodality tumor imaging.
2 Review
Molecular imaging of living organisms involves the
visualization of biological processes and cellular func-
tions at the molecular and cellular levels [33]. This
can be used for diagnosis of diseases such as cancer,
neurological, and cardiovascular conditions without
any invasion to the living organism [1,3]. In general,
the field of molecular imaging for clinical use includes
magnetic resonance imaging (MRI), computed tomog-
raphy (CT), positron emission tomography (PET), single
photon emission computed tomography (SPECT), con-
trast enhanced ultrasound (CEUS), and optical fluores-
cence. Taking into account sensitivity, spatial resolution,
and temporal depth resolution, each molecular imaging
tool has different sets of capabilities [6]. For instance, the
lack of penetration depth limit of PET and SPECT,
coupled with their high sensitivity (down to the picomolar
range) and quantitative abilities make them powerful tools
for in vivo imaging [34]. Molecular imaging includes the
administration of imaging probes and the detection of
specific signals produced from the probes. In PET, the sys-
tem detects pairs of gamma rays emitted by positron-
emitting radionuclides [35]. Positrons interact with nearby
electrons at a distance of ~1 mm, transmutating to gener-
ate and emit 511 keV gamma photons. To enable this
process, various positron-emitting isotopes are available
for PET imaging. Among them, 18 F and 64Cu are attract-
ive radionuclides for site-specific imaging. Fluorodeoxy-
glucose (FDG) is the most commonly used radiotracer for
tumor-targeted imaging. It is taken up by cells with a high
need for glucose such as those in the heart, brain, and
tumor [36]. 64Cu is also a good candidate to be labeled
onto biomolecules like antibodies and peptides due to its
proper decay half-life, relatively low energy, and commer-
cial availability [2]. In SPECT, computer-generated three-
dimensional images of radioactive tracers are produced by
detecting single gamma ray photons [37]. A single gamma
photon is generated when each radionuclide decays from
a higher energy state to a lower state. SPECT imaging uses
gamma emitting radioisotopes such as 93mTc, 111In, 123I,
and 131I.
Nanostructures, which range in size from 1 to 100 nm,
have a high surface area to volume ratio and strong,
controllable binding capacity for specific molecules. This
allows for varied surface modification and the multiva-
lent binding of targets, which suggests new applications
in molecular imaging and nanomedicine [38-48]. While
active targeting is advantageous, the most important
factor of nanostructure development for bioimaging is
the enhanced permeability and retention (EPR) effectdue to the leakage of neovasculature in tumor. The
EPR effect is the property that only molecules and par-
ticles of specific sizes accumulate in tumor tissues. The
effect is due to the abnormal angiogenesis caused by
various growth factor stimulation in tumor tissues [49].
Nanostructures of 100 nm in diameter can be optimum
candidates for maximizing the EPR effect in vivo. More-
over, modifying surface charge and flexibility allow control
of nanostructure biodistribution [43,46,50]. For nanoparti-
cles with different surface properties and multifunctional
groups, proper isotope and radiolabeling methods need to
be considered carefully for optimized imaging outcome.
After labeling with a radionuclide, functionalized nano-
structures can serve as good candidates for molecular im-
aging probes (PET or SPECT). The two major strategies
for labeling nuclides onto nanostructures depend on
whether or not chelating agents are used. The chelation-
free labeling methods include self-radioactive nanostruc-
tures and the direct attachment of radionuclides onto
the nanostructures, which both utilize specific interac-
tions between the radioisotope and the nanostructure.
In the earlier examples of this work, radionuclides
(radioisotopes), which are used as radiotracers for nu-
clear molecular imaging (PET or SPECT), were com-
bined with nanoparticles, including gold nanoparticles
[18,19,51], carbon-based nanomaterials [20-22,52], and
quantum dots [53,54], through a chelating agent, such
as DOTA, NOTA, and others [55]. Moreover, chlor-
amine T can act as an oxidizing agent in the synthesis of
the Bolton-Hunter reagent to label radioactive iodine [56].
Although many chelating agents were tested to label ra-
dioisotopes more efficiently, DOTA is the most attrac-
tive candidate due to its FDA approval for human
application.
2.1 Chelating agent-mediated nanostructures
2.1.1 Gold nanostructures
Colloidal gold nanoparticles (AuNPs) are attractive
candidates as imaging probes because of their low
cytotoxicity in a variety of cell and animal models
[32,57-60]. Moreover, AuNPs can be easily modified
with biomolecules (e.g., DNA and peptides) via thiol-
Au bonds, and many other functional ligands can also
be incorporated. Xie et al. reported a 64Cu-chelated
gold nanoshell (AuNS) structure for in vivo PET im-
aging and photothermal therapy [18]. For this, the bi-
functional chelating agent p-NH2-Bn-DOTA (S-2-(4-
aminobenzyl)-1,4,7,10-tetraazacyclododecane tetraace-
tic acid) was conjugated to bifunctional OPSS-PEG2K-
NHS (opyridyldisulfide-polyethylene glycol 2000-N-
hydroxysuccinimide) (Figure 1(a)). About 90% of the
resulting 64Cu-chelated AuNS was stable for 3 hrs in PBS
solution or serum, and showed accumulation in the
squamous cell carcinoma region by the EPR effect. In
Figure 1 In vivo PET imaging of radiolabeled gold nanoshell structure with tumor. (a) Synthesis of radiolabeled AuNS conjugates.
(b) Pharmacokinetics, expressed as the percentage of the injected dose (%ID), of 64Cu-DOTA, 64Cu-DOTA-PEG2K, and 64Cu-NS at 0, 4, 20,
and 44 h p.i. Significantly different pharmacokinetics between 64Cu-NS and the two controls are evident at 4 h p.i. (p <0.05). (c) PET images at
different time points with three different probes. (64Cu-DOTA, 64Cu-DOTA-PEG2K, and 64Cu-NS) (d) Biodistribution of 64Cu-NS in several major organs.
(Adapted with permission from Ref. 18. Copyright (2010) Elsevier).
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(12.76 hrs), was significantly longer than the half-lives of
the 64Cu-DOTA and 64Cu-DOTA-PEG2K controls (0.54
and 0.52 hrs, respectively). As shown in Figure 1(b), statis-
tical analysis proved that 64Cu-NS had a much higher
remaining ratio in the blood at 4 hrs post-injection (p.i.)
than the two controls (32.1 ± 1.8% ID vs. 13.9 ± 6.8 and
11.0 ± 6.2% ID; p <0.05) (Figure 1(c,d)). Yucai et al. fur-
thermore reported a 64Cu-labeled DOTA-PEG-Au nanoc-
age (64Cu-DOTA-PEG-AuNC) for simultaneous in vivo
tumor targeted PET imaging and pharmacokinetics [19].
AuNCs have effective photothermal translation activity,
capable of converting light into heat and increasing the
local temperature. Therefore, AuNCs can act as aphotothermal therapeutic agent while its properties as an
imaging agent allows simultaneous monitoring of its bio-
distribution. DOTA was conjugated onto the AuNC sur-
face using an NH2-modified PEG molecule for labeling
radionuclide as a PET imaging agent. The NH2 groups
were then coupled with DOTA-NHS-ester through an
amide reaction via an NHS-activated ester, followed
by chelation with 64Cu ions. 64Cu-DOTA-PEG-AuNCs
showed 81.5% stability following a 24 hr incubation in
serum. Due to the reduction in size and surface charge,
the 30 nm diameter 64Cu-DOTA-PEG-AuNCs showed
improved in vivo pharmacokinetics with decreased RES
system uptake and enhanced blood circulation compared
to the 55 nm samples.
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Due to their unique geometric, chemical, and physical
properties, carbon nanotubes are promising candidates for
nanomedicine [61-64]. SWNT can be non-covalently func-
tionalized with phospholipid-PEG for sustained solubility
and stability in human serum environments [20]. The ter-
mini of PEG on the nanotube can be furthermore conju-
gated to both DOTA and integrin αvβ3, with the integrin
targeting the RGD (arginine-glycine-aspartic acid) peptide
for 64Cu labeling and tumor imaging. Liu et al. found that
SWNT chelated with 64Cu in this way showed high tumor
accumulation over long periods (~24 hrs).
Graphene oxide (GO) is a type of planar carbon sheet
that has a great potential in nanomedicine due to its in-
teresting properties arising from the combination of an
ultrahigh surface area with a modifiable planar surface
chemistry [65,66]. Though toxic in some cases, the bio-
compatibility of graphene oxide is dependent on the
functional groups displayed [67]. For example, poly-
ethylene glycol (PEG) functionalized GO can be ex-
creted through the urinary tract, without inducing
cytotoxicity [68]. Hong et al. developed 66Ga and 64Cu-
chelated GO for tumor vasculature imaging [21,69].
The researchers used 1,4,7-triazacyclononane-1,4,7-triace-
tic acid (NOTA) for chelating both 66Ga and 64Cu. NOTA
and TRC 105 (antibody binding to CD105) were cova-
lently conjugated to agraphene oxide sheet consisting of
six-arm branched PEG molecules on the surface (Figure 2
(a)). More than 90% of labeled 66Ga and 64Cu remained
on the GO conjugates during a 48 hrs incubation in serum
conditions (Figure 2(b)). Efficient tumor uptake of
radiolabeled-NOTA-GO-TRC105 occurred with a clear
visualization at early time points and a stability over
48 hrs (Figure 2(c,d)). Cornelissen et al. used doxorubicin
and 111In-loadedgraphene oxide (GO) for tumor targeted
SPECT imaging and therapy [22]. Different from Hong
et al., they labeled 111In using π-π stacked benzyl-
DTPA onto GO. The 111In achieved a labeling yield of
98% and only less than 5% of chelated 111In was lost by
transchelation to serum proteins during serum incubation.
111In-labeled NGO-trastuzumab constructs (which con-
sisted of an antibody against HER2) were shown to target
HER2 receptors with high specificity.
2.1.3 Lipid nanostructures
Liposomes are clinically well-established drug delivery
vehicles with properties including biocompatibility, high
drug-to-carrier ratios, and straightforward drug encapsu-
lation capability [70-73]. The polar and non-polar do-
mains of the molecules comprising the liposome structure
allow the stable encapsulation of both hydrophilic and
hydrophobic agents. The incorporation of hydrophilic
polyethylene glycol on the surface of liposomes further im-
proves their properties of low opsonization and longcirculation time [43]. Seo et al. reported a novel 64Cu label-
ing method for liposomes [23]. The researchers conjugated
a 64Cu specific chelating agent, 6-[p-(bromoacetamido)
benzyl]-1,4,8,11-tetraazacyclotetradecane-N,N’,N”,N”’-
tetraacetic acid (BAT) to an artificial lipid molecule
to form a BAT-PEG-lipid, followed by successfully in-
corporating 64Cu into liposomes at pH 5. About 88% of
64Cu was encapsulated into the liposomes over the
course of a 48 hr serum incubation. Different from the
above method, Petersen et al. demonstrated remote
loading of 64Cu into a liposome using a novel inophore,
2-hydroxyquinoline [24]. By remote loading, the radio-
nuclide becomes entrapped in the aqueous core of the
liposome, rather than on the surface. For the remote
loading mechanism, 2-hydroxyquinoline carries 64Cu
across the lipid membrane to the aqueous portion of
liposome, followed by chelation into pre-encapsulating
DOTA (Figure 3(a)). Using this technique, the re-
searchers achieved very efficient loading (95.5%) and re-
tention stability (>99%), which shows the 64Cu-
liposomes to be promising PET imaging agents. This
method provides maximized and stable 64Cu labeling
efficiency. PEG conjugated liposomes can circulate for
an extended time and are able to accumulate in tumor
regions through the EPR effect. The 64Cu-liposomes
remained in the blood-pool for over 24 hrs. The 64Cu-
liposome activity at the tumor site increased over the
24 hr time period post injection. This result means that
the number of 64Cu-liposomes delivered to the tumors
continues to accumulate as long as liposomes are cir-
culating in the blood stream (Figure 3(b)).
2.2 Chelating agent-freenanostructures
2.2.1 The need for labeling strategies free of chelating
agents
Although various chelating agent-mediated radioisotope
labeled nanoprobes have been suggested for nuclear
molecular imaging and pharmacokinetics, chelating
agent-mediated functionalization methods have several
limitations for nanoparticles used in vivo [28]. Firstly,
the functionalized radionuclides using chelating agents
at the surface of nanoparticles can induce the change
of intrinsic surface properties of nanoparticles, such as
surface charge, polarity, and degree of hydrophobicity.
Basically, the physicochemical properties of nanoparti-
cles are strongly affected by their surface conditions
[74], and therefore, chelating agent-functionalized
nanoparticles may show different biodistributions or
pharmacokinetic properties than compared to non-
functionalized nanoparticles. Secondly, radionuclides
incorporated with a chelating agent may be influenced
by harsh conditions in vivo, resulting in the detach-
ment of radionuclides during circulation or their re-
placement by biological substances due to protein
Figure 2 In vivo targeting and PET imaging using 64Cu-labeled nano-graphene. (a) Schematic representation of conjugated nano-graphene.
(b) Serum stability test of 64Cu-labeled nano-graphene shows that the vast majority of 64Cu remains intact on the GO after incubation in complete
mouse serum at 37°C for 48 hrs. (c) In vivo PET/CT imaging of 64Cu-labeled GO conjugates in 4 T1 murine breast tumor-bearing mice. Serial coronal
PET images of 4 T1 tumor-bearing mice at different time points post injection (p.i.) of 64Cu-NOTA-GO-TRC105, 64Cu-NOTA-GO, or 64Cu-NOTA-GO-TRC105
after a preinjected blocking dose of TRC105. Tumors are indicated by arrowheads. (d) Biodistribution studies in 4 T1 tumor-bearing mice. Biodistribution of
64Cu-NOTA-GO-TRC105 and 64Cu-NOTA-GO in 4 T1 tumor-bearing mice at 3 hrs and 48 hrs postinjection; *p < 0.05. Biodistribution of
64Cu-NOTA-GO-TRC105 and 64Cu-NOTA-GO-TRC105 after a blocking dose of TRC105 (denoted as blocking) in 4 T1 tumor-bearing mice at
48 h p.i. (Adapted with permission from Ref. 21. Copyright (2012) American Chemical Society).
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these instabilities of radionuclide-chelating agent com-
plexes decrease the accuracy of pharmacokinetics and
diagnosis data [75]. To avoid these disadvantages, re-
searchers have been developing labeling strategies free
of chelating agents. One of these studies, by Gibson
et al., carried out direct radiolabelling using cyclotron
accelerators to incorporate radionuclides into nanoma-
terials directly [76]. However, this direct incorporation
method, which used neutron bombardment to generate
high energy radiation, damaged the nanomaterials by
causing them to aggregate.2.2.2 Radio-labeled nanostructures free of chelating agents
Recently, nanoprobes free of chelating agents have been re-
ported for nuclear molecular imaging [28-32]. To synthesize
these, researchers have created self-radioactive nano-
particle probes using radioisotopes of metal atoms,
such as 64Cu or 198Au, or by directly attaching radioiso-
topes, e.g. 125I, onto the metal nanoparticle surface
without a chelating agent. For example, Zhou et al. syn-
thesized ~11 nm diameter [64Cu]CuS nanoparticles for
micro-PET/CT imaging and as a photothermal coupling
agent for photothermal ablation, without the use of
chelating agents [28] (Figure 4(a-c)). The [64Cu]CuS
Figure 3 64Cu loaded liposome for tumor imaging using PET. (a) Remote loading of 64Cu into preformed liposomes using an
ionophore, 2-hydroxyquinoline. Over 99% of encapsulation efficiency was obtained with size exclusion chromatography after a remote
loading method. (b) Coronal PET image 24 hrs post-injection of 64Cu-liposomes into a mouse bearing colon adenocarcinoma (marked with
arrows) on right and left flank. (Adapted with permission from Ref. 24. Copyright (2011) Elsevier).
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showed high radiolabeling efficiency and stability in PBS or
serum environments. These [64Cu]CuS nanoparticles also
showed high uptake in U87 human glioblastoma (U87MG)
xenografts through enhanced permeability and retention ef-
fects. Furthermore, the [64Cu]CuS nanoparticles strongly
absorbed near-infrared (NIR) radiation (with a peak adsorp-
tion at 930 nm), and thus, they could be applied to the
photothermal ablation of U87MG tumor cells upon expos-
ure to NIR light. Therefore, these unique properties, such
as small diameter, incorporation of 64Cu as a radio-
tracer, high radiolabeling efficiency, excellent stability,
and strong NIR absorption, are ideally useful for multi-
functional molecular imaging and therapy. Similarly,
Black et al. synthesized the radioactive 198Au-doped
nanostructures by directly incorporating radioactive 198Au
isotopes with non-radioactive 197Au atoms during synthe-
sis [29]. To use nanoparticles forin vivo theragnosis, the
in vivo properties of nanoparticles including biodistribu-
tion, tumor uptake, and intratumoral distribution should
be investigated and analyzed accurately. Since the
in vivo properties of nanoparticles depend on their
physicochemical characteristics including geometry,
Black et al. synthesized four differently-shaped nano-
structures: nanospheres, nanodisks, nanorods, and
cubic nanocages, with similar sizes to confirm the
shape-dependent behavior of nanoparticles using a murine
EMT6 breast cancer model. They found that 198Au-incor-
porated nanospheres showed optimal behavior with thebest blood circulation, the lowest clearance by the reticu-
loendothelial system (RES), and the highest tumor uptake.
These 198Au-incorporated nanostructures have a great po-
tential for in vivo molecular imaging compared to the dis-
advantages of radioactive nanomaterials made with
chelating agents. Lately, the radioactive 64Cu-alloyed [30] or
64Cu-integrated [31] Au nanoparticles were synthesized for
improving radiolabel stability and diagnostic accuracy, as
well as PET imaging guided photothermal cancer therapy.
Unlike self-radioactive nanoparticles composed of radioiso-
topes, Kim et al. synthesized cyclic RGD-PEGylated Au
nanoparticle probes with surface conjugated radioactive 125I
for tumor targeting and SPECT/CT [32] (Figure 4(d-f)).
The surface conjugation of 125I works by the high affinity
binding between the iodine ion and the Au surface
[17,77-79]. This simple labeling chemistry provided high
stability for ~20 hrs in serum or under various pH and high
salt conditions with tumor-specific targeting for ανβ3 integ-
rin expressing tumor cells via ανβ3-receptor-mediated
endocytosis. Importantly, the 125I-labeled cRGD-PEG-Au
nanoprobes could target the tumor site only 10 min. after
intravenous injection as observed by SPECT/CT imaging,
and could be excreted from the body by renal clearance
without any sign of toxicity.
2.3 Radionuclide-labeled nanostructures for multimodality
tumor imaging
Generally, molecular imaging tools, such as positron
emission tomography (PET), single photon emission
Figure 4 Chelator-free nanoprobes for nuclear molecular imaging. (a) Biodistribution of Cit-CuS NPs (n = 5) and PEG-CuS NPs (n = 5) at 24 h
after i.v. injection in tumor-bearing mice. (b) Micro-PET/CT images of tumor-bearing nude mice acquired at 1, 6, and 24 h after i.v. injection of
PEG-[64Cu]CuS NPs. Yellow arrow = tumor; orange arrow = bladder, red arrow = standard. (c) Photographs of mice bearing subcutaneous
U87 tumor before and at 24 h after NIR laser irradiation (upper panel). Representative microphotographs of tumors removed 24 h after NIR
laser treatment (lower panel). Abbreviations: Cit-CuS NPs = citrate-coated CuS nanoparticles; PEG-CuS NPs = PEG-coated CuS nanoparticles;
i.v. = intravenous; NIR = near-infrared. (d) Synthesis of cyclic RGD-PEGylated-AuNP probes labeled with radioactive iodine-125. (e) TEM images of
cellular uptake after treated with 125I-cRP-AuNPs, U87MG cells (upper panel) and MCF-7 cells (lower panel). Arrows indicate cellular uptake of
125I-cRP-AuNPs in cells. (f) Small-animal SPECT/CT of 125I-cRP-AuNPs (upper panel), and cold-form-blocked 125I-cRP-AuNPs (lower panel) in nude
mice bearing U87MG tumors xenografts after injection through tail vein. Yellow circles indicates tumor region (a-c adapted with permission from
ref. 28. Copyright (2010) American Chemical Society & d-f adapted with permission from ref. 32. Copyright (2011) Wiley).
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imaging (MRI), contrast-enhanced ultrasound (CEUS),
and optical fluorescence, have intrinsic advantages and
drawbacks simultaneously for accurate tumor imaging.
For example, PET and SPECT are powerful imaging
tools due to their high sensitivity, quantitative nature,
and lack of a penetration limit, however, they are not
perfect for single modality because of their low spatial
resolution [6]. MRI enables morphological and func-
tional imaging with no penetration limit and a high
spatial resolution, however, it is limited by its low sen-
sitivity. Optical fluorescence is widely used for molecu-
lar imaging given its low expense and high sensitivity,
however, it also has several drawbacks, such as low
spatial resolution, limited penetration, photobleaching,
and autofluorescent emission from tissues and biomole-
cules. With such a wide range of capabilities, molecular
imaging tools should be combined to enhance overall
image quality.2.3.1 PET(SPECT)/MR imaging
MRI is the most widely used non-invasive diagnostic
technique based on the interaction of protons with sur-
rounding molecules in the target tissue [80]. MRI pro-
vides several advantages, including high temporal and
spatial resolution, soft tissue contrast, and the absence
of ionizing radiation, which radionuclide-based imaging
techniques, such as PET and SPECT, cannot achieve.
However, MRI is limited by its low sensitivity and long
acquisition time compared to PET and SPECT. Thus, as
complementary techniques, PET (or SPECT) and MRI
can be combined to overcome their individual limitations.
The most commonly used nanoparticle-based MRI con-
trast agents are superparamagnetic iron oxide nanoparti-
cles (SPIONPs), which are composed of Fe3+ and Fe2+
[81]. Usually, radionuclides are conjugated to iron oxide
nanoparticles (IONPs) using chelating agents on the sur-
face of IONPs for simultaneous dual-modal imaging tech-
niques including PET and MRI. Lee et al. synthesized
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nanoprobes with RGD peptide as a targeting moiety for
ανβ3 integrin over-expressed U87MG tumor cells to apply
PET/MR dual-modal imaging [82] (Figure 5). These probes
were polyaspartic acid (PASP)-coated IO (PASP-IO) nano-
particles with a core size of 5 nm and a hydrodynamic
diameter of 45 ± 10 nm, and the saturation magnetization
of PASP-IO nanoparticles was about 117 emu/g of iron.
With RGD conjugation, displacement competitive binding
assays showed that these RGD-PASP-IO assemblies could
bind specifically to integrin ανβ3 in vitro. Furthermore,
small-animal PET, T2-weighted MRI, and histologic
analysis showed integrin-specific delivery of conju-
gated RGD-PASP-IO nanoparticles and prominent reticu-
loendothelial system (RES) uptake. Instead of 64Cu, Choi
et al. labeled 124I on the surface of albumin-coated
magnetic nanoparticles composed of MnFe2O4 via theFigure 5 PET(SPECT)/MR imaging. (a) Preparation of PET/MRI dual-moda
N”,N”’-tetraacetic acid; IO = Iron Oxide; RGD = arginine-glycine-aspartic; PEG
(b) Decay-corrected whole-body coronal PET images of human U87MG tum
64Cu-DOTA-IO, 64Cu-DOTA-IO-RGD, or 64Cu-DOTA-IO-RGD (left). Time-activit
64Cu-DOTA-IO-RGD, or 64Cu-DOTA-IO-RGD with blocking dose of c(RGDyK)
tumor-bearing nude mice before injection of IO nanoparticles (c-1 and c-5
DOTA-IO-RGD (c-3 and c-7), and DOTA-IO-RGD with blocking dose of c(RGD
spleen sections after injection of 64Cu-DOTA-IO-RGD, 64Cu-DOTA-IO, and 64Cu
spots in figure (magnification, 200x). (Adapted with permission from ref. 82. Ctyrosine residue in the albumin. These probes were
used for dual-modality PET/MR imaging [83]. Unlike
PET/MR dual-modal imaging, Misri et al. synthesized
dual-modal imaging probes for SPECT/MR by conju-
gating 111In labeled antimesothelin antibody (mAbMB)
to SPIONPs [84].
2.3.2 PET(SPECT)/optical imaging
Optical fluorescence, especially near-infrared fluorescence
(NIRF) imaging technique, is most widely used for mo-
lecular imaging due to its high sensitivity, rapid scanning
time with relatively inexpensive imaging instruments,
and low risk to living organisms as it uses nonionizing
rather than ionizing radiation. However, this imaging
technique suffers from low tissue penetration, leading to
poor quantification [6]. By combining fluorescence with
radionuclide-based imaging techniques (PET or SPECT),lity probe DOTA-IO-RGD. DOTA = 1,4,7,10-tetraazacyclododecane-N,N’,
-MAL = poly(ethylene glycol)-maleimide; PASP = polyaspartic acid.
or-bearing nude mouse at 1, 4, and 21 h after injection of
y curves of U87MG tumors after injection of 64Cu-DOTA-IO,
(n = 3/group) (right). (c) T2-weighted MR images of U87MG
) and at 4 h after tail-vein injection of DOTA-IO (c-2 and c-6),
yK) (c-4 and c-8). (d) Prussian blue-stained U87MG tumor, liver, and
-DOTA-IO-RGD with blocking dose of c(RGDyK). IO was stained as blue
opyright (2008) The Society of Nuclear Medicine and Molecular Imaging).
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aging quality. Especially useful for imaging applications,
quantum dots (QDs) are nanometer-sized inorganic fluor-
escent semiconductor crystals with excellent optical prop-
erties such as high quantum yield and molecular
extinction coefficients, along with low photo-bleaching
and composition-tunable absorption and emission spectra
ranging from ultraviolet to near-infrared [45,85,86]. By
introducing radionuclides using a chelating agent on the
surface of QDs, PET (or SPECT) and NIRF dual-modal
imaging techniques can be used. Cai et al. successfully
synthesized QDs-based PET/NIRF imaging probes by
conjugating QDs with cyclic RGD peptide for targeting
and imaging tumors (integrin ανβ3 expressing U87MG
tumor xenografts) [54] (Figure 6). In that work, DOTA
was introduced as a chelating agent for incorporating ra-
dionuclides, with 64Cu and CdTe QDs used for NIRFFigure 6 PET(SPECT)/optical imaging. (a) Preparation of dual functional PE
N’,N”,N”’-tetraacetic acid; QD = Quantum Dot; RGD = arginine-glycine-aspartic
tumor with dual functional PET/NIRF probe. Whole-body coronal PET images
DOTA -QD -RGD. Arrows indicate tumors. GI = gastrointestinal tract; L = liver.
after injection of 64Cu-labeled DOTA-QD-RGD. (d) Histologic analysis of DOTA
bright-field and QD fluorescence images of frozen tissue slices (5 μm thick) (le
tumor slices from mice injected with 64Cu-labeled DOTA-QD-RGD (right). (Ada
Nuclear Medicine and Molecular Imaging).imaging. These dual-modal imaging probes showed excel-
lent tumor uptake behavior, and a linear correlation be-
tween PET and NIRF signal intensities was confirmed.
Furthermore, QD-based PET/NIRF imaging probes sig-
nificantly reduced the potential toxicity and overcame the
tissue penetration limit of optical imaging. In another
study, Liang et al., reported SPECT/NIRF tumor imaging
probes using streptavidin coated nanoparticles [87]. These
streptavidin nanoparticles were conjugated with three
types of molecules: biotinylated anti-Her2 Herceptin anti-
bodiesto target a SUM190 (Her2+) tumor, biotinylated
DOTA chelating agents for labeling of radionuclides (111In),
and biotinylated Cy5.5 fluorophores for NIRF imaging. The
SPECT/NIRF imaging displayed high tumor accumulation
and strong tumor-to-normal tissue contrast, and the
specific tumor accumulation of radioactivity at 40 h
was 21 ID%/g, which denoted a higher accumulationT/NIRF probe DOTA-QD-RGD. DOTA = 1,4,7,10-tetraazacyclododecane-N,
acid; PEG = polyethylene glycol. (b) In vivo PET of mice bearing U87MG
of mice at 1, 5, 18, and 25 h after injection of 64Cu-labeled DOTA -QD or
(c) Ex vivo PET (left) and NIRF (right) image of harvested tissues at 5 h
-QD-RGD distribution in U87MG tumors and other tissues. Overlay of
ft). Immunofluorescence staining (CD31 and mouse β3) of frozen U87MG
pted with permission from ref. 54. Copyright (2010) The Society of
Figure 7 (See legend on next page.)
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Figure 7 PET(SPECT)/MR/optical imaging. (a) Reflection and confocal images of A431 cells labeled with NOTA-Au-IONP-Affibody (left). NOTA =
1,4,7-triazacyclononane-1,4,7-triacetic acid; IONP = iron oxide nanoparticle. Quantification analysis of the cellular uptake with NOTA-Au-IONP,
NOTA-Au-IONP-Affibody, and Affibody blocked NOTA-Au-IONP-Affibody in A431 cells after incubation (right). (b) In vivo decay-corrected whole-
body coronal PET images of A431 tumor bearing mice (n = 3/group) (left). Quantitative analysis of PET images of tissues and organs (right). (c)
In vivo T2-weighted MR images of A431 tumor bearing mice (left). Quantification of MRI signal intensity before and at 4 h and 48 h after injection
of 64Cu-NOTA-Au-IONP-Affibody and Affibody (right). (Adapted with permission from ref. 89. Copyright (2013) Elsevier).
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heart, kidney, spleen, and muscle.
2.3.3 PET(SPECT)/MR/optical imaging
With the easily modifiable surface chemistry of nanopar-
ticles, two or even more imaging labels can be intro-
duced to a single nanoparticle with multiple linking
agents (ligands) or direct-incorporation. With this ex-
pansive nature, nanoprobes can be designed for imaging
modalities beyond two modes. Recently, such multi-
functional imaging probes containing three different im-
aging modalities have been developed [88-91]. Park et al.
successfully synthesized optical/PET/MR hybrid nanop-
robes by conjugating a PET radionuclide (124I) to an
MRI probe (SPIONPs) [88]. These optical/PET/MR hy-
brid nanoprobes could screen lymph node metastasis
with high sensitivity using optical imaging and then pro-
vide accurate 3D visualization of accumulated nanop-
robes with detailed anatomical information using PET
and MR imaging. Yang et al. also provided Affibody
modified and radiolabeled Au-IO hetero-nanostructures
for tumor optical/PET/MR-based multi-modal imaging
probes using NOTA as a chelating agent for a 64Cu radio-
nuclide [89] (Figure 7). Such hetero-nanoprobes can show
surface-specific modification of both targeting molecules
(anti-EGFR Affibody protein) and PET imaging reporters
(64Cu) with high efficiency and reliability. The NOTA-Au-
IONP-Affibody was very stable in 10% fetal bovine serum
in PBS at 37°C for 48 h with little variation of particle size.
By taking advantage of the plasmonic properties of AuNPs
imaging, the NOTA-Au-IONP-Affibody could be used for
cell assays with a scanning confocal microscope. For both
PET and MR imaging, in vitro and in vivo studies showed
high specificity, sensitivity, and excellent tumor contrast
in human EGFR-expressing cells and tumors. Xie et al.
functionalized dopamine to the surface of IONPs for facile
encapsulation into human serum albumin (HSA) matrices,
and labeled both 64Cu-DOTA and Cy5.5 onto the HSA
coated IONPs to enable PET/MR/NIRF multi-modal im-
aging [90]. In vivo PET/NIRF/MR tri-modality imaging,
and ex vivo analyses, indicated that the 64Cu-DOTA and
Cy5.5 labeled HSA-IONPs have a good retention and high
extravasation rates at the tumor site. Impressively, HSA-
IONPs showed a prolonged circulation half-life, high ac-
cumulation in lesions, and low uptake of the particles by
macrophages due to compact HSA coating. Unlike IONP-based MR imaging, Lee et al. reported RGD peptide-
conjugated multi-modal Yb3+/Er3+ co-doped NaGdF4
upconversion nanophosphors for PET/MR/optical im-
aging of tumor angiogenesis [91]. In their report, Gd, a
component of nanophosphors, was used as a T1-weighted
MRI contrast agent rather than IONPs. The assembly was
radiolabeled with 124I and conjugated with a tyrosine resi-
due of dimeric cyclic RGDyk peptide targeting integrin
αvβ3, and Yb
3+/Er3+ was doped to enable fluorescence im-
aging. These multi-modal imaging techniques are benefi-
cial for real clinical applications, such as early diagnosis,
by maximizing detection at different levels. However, the
synthesis of nanostructures for multimodal imaging can
present challenges of its own, as steps in synthesizing one
mode may interfere with another. Thus, the synthetic pro-
cedure must be planned carefully to achieve ideal activity
from each imaging mode in the finished product [92].
3 Conclusions
A variety of nanostructures have been utilized for
in vivo diagnostic and therapeutic agents. In this review,
nanostructures labeled with radionuclides were intro-
duced for in vivo tumor imaging. Although many chelat-
ing agents have been used to incorporate radionuclides
into nanostructures for molecular imaging, there is a need
to develop radionuclide labeling strategies free of chelating
agents for in vivo nuclear molecular imaging accuracy
while maintaining biocompatibility. Moreover, multimod-
ality molecular imaging should be used to overcome
limitations in the imaging quality of a single modality.
Although multimodality tumor imaging techniques
have been developed remarkably over the past decade,
most of those techniques have not moved beyond basic
research. More effort should focus on the clinical ap-
plications of nanostructures for multimodality imaging.
Given the insights that these allow into different
physiological properties of tumors and disease, these
nanostructures will likely to generate advancements in
diagnosis and therapy across a wide range of medical
fields.
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